Back

Lipoprotein(a) levels and cholesterol efflux capacity: inverse association and impact on atherosclerosis in familial hypercholesterolemia patients on lipid-lowering therapy

31 August 2024 (12:00 - 12:50)
Organised by: Logo
Congress Presentation Part of: Familial hypercholesterolaemia and cardiovascular risk Lipids ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Masatsune Ogura

Juntendo University Urayasu Hospital, Urayasu (Japan)

7 More presentations in this session

Presentation thumbnail
Impact of addressing modifiable risk factors on the 10-year risk of cardiovascular disease in individuals with familial hypercholesterolemia: a causal analysis utilising UK biobank
Mr C. Stevens (London, GB)
Abstract Slides Video
Presentation thumbnail
Impact of the severe familial hypercholesterolemia status on atherosclerotic risks
Doctor H. Tada (Kanazawa, JP)
Abstract Slides Video
Presentation thumbnail
The effectiveness and barrier of reverse cascade screening for paediatric familial hypercholesterolaemia
Doctor R. Tani (Kagawa, JP)
Abstract Slides Video
Presentation thumbnail
Screening for subclinical atherosclerosis in patients clinically diagnosed with familial hypercholesterolemia and determination of imaging-guided patient management strategy
Doctor M. Deniz (Istanbul, TR)
Abstract Slides Video
Presentation thumbnail
Impact of changes of Achilles tendon thickening on cardiovascular events among patients with familial hypercholesterolemia
Doctor H. Tada (Kanazawa, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Familial hypercholesterolaemia and cardiovascular risk

The Event

Event poster

ESC Congress 2024

31 August 2024 12:00 CET
You may be interested in
thumbnail
Congress Presentation
Increased Lipoprotein (a) and familial hypercholesterolemia: a dangerous combination.Data from a 12-year follow-up study
thumbnail
Congress Presentation
The impact of very highly elevated lipoprotein(a) levels on the early onset, complexity, and extent of coronary artery disease
thumbnail
Congress Session
Late-Breaking Clinical Science: lipids and cardiovascular risk

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources